Of course, the objective is to produce health benefits, not just switch genes. Indeed, these small molecules did just that. Plain resveratrol and Longevinex both protected heart tissues and reduced the size of a heart attack, as measured by the amount of scar tissue (fibrosis).
Longevinex reduced the size of a heart attack (from ~35% without treatment to ~20% scar tissue with treatment) in a superior manner to plain resveratrol (from ~35% to ~24% scar tissue), and reduced death of heart muscle cells (cardiomyocytes) from ~17% without treatment to ~9% with Longevinex (48% reduction in cell death), compared to a decline from ~17% to ~12% with plain resveratrol (20% reduction in cell death).
While plain resveratrol modestly improved the pumping pressure of the heart (from ~75 to ~90 millimeters of mercury pressure; 20% improvement), Longevinex doubled heart pumping pressure (from ~70 to ~140 millimeters of mercury pressure; 100% improvement) compared to no treatment at the two-hour point following an experimentally-induced heart attack.
Also at the two-hour point, Longevinex improved blood flow in the aorta (first blood vessel outside the pumping side of the heart) from ~15 milliliters per minute without treatment to ~26 milliliters per minute (73% improvement), while resveratrol improved blood flow from ~14 milliliters per minute without treatment to ~21 milliliters per minute (50% improvement).
Back to microRNA switching
Upon analysis, it became clear that Longevinex exerted the greatest influence over the top 25 significantly differentiated microRNA's in rodent heart tissue. Longevinex exceeded the effect of resveratrol in 15 of the 25 microRNA's.
Comparative analysis of three key microRNA (microRNA 20b, 21, 539) are instructive.
Longevinex profoundly down-regulated microRNA 20b (-1366-fold) compared to plain resveratrol (-189-fold), a microRNA that exerts control over a gene (h
|Contact: Bill Sardi|
Resveratrol Partners LLC, dba LONGEVINEX